Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Available Options: 30-Day Supply (10 ml Vial, 10 at 1,000 mcg/mL)
Understanding interactions and synergies helps develop comprehensive management strategies
revealed that miR-182 binds to MET in breast cancer cells and suppresses the cell's ability to tolerate trastuzumab, therefore reducing the invasion and migration capability of trastuzumab-resistant cells through MET-dependent PI3K/AKT/mTOR signaling pathways (Yue and Qin, 2019)
Between 1% and 10% of the lysate was retained as input control, and the remaining lysate was used for immunoprecipitation
US$ 24.04
US$ 23.52
US$ 27.97
US$ 21.60
US$ 22.03
